ANI Pharmaceuticals Announces Intent to Acquire Egetis Therapeutics for $560 Million

ANI Pharmaceuticals has announced a recommended public offer to acquire Swedish rare disease drugmaker Egetis Therapeutics for approximately $560 million. The acquisition, valued at SEK 11.25 per share, aims to expand ANI's rare disease portfolio by adding Emcitate, Egetis' recently FDA-approved drug. Egetis' board and shareholders controlling about 42% of the company support the deal.